Login
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc.

boltbio.com

What Do They Do?

Develops immune-based cancer drug candidates, including antibody-linked immune stimulators, for cancer patients.

How Do They Make Money?

Collaboration partners provide upfront payments, fund research, and reimburse development costs; Bolt earns collaboration revenue as it performs research and development services. Some agreements also provide milestone payments and royalties on sales.

FY2025 revenue

Who Are Their Customers?

Companies such as Toray, Genmab and Innovent collaborate with Bolt on oncology research and development; Genmab funds research and early development, and Toray shares development costs with Bolt.

Do Revenues Turn Into Profits?

No. It lost $33.4M in FY2025.

Operating income, FY2025
−469% of revenue
▲ +51% (Loss) vs FY2024 (−$73M, −950%)
Net income, FY2025
−434% of revenue
▲ +47% (Loss) vs FY2024 (−$63.1M, −821%)
Free cash flow, FY2025
−519% of revenue
▲ +35% (Loss) vs FY2024 (−$61.3M, −798%)

How Are They Changing?

Since the FY2025 annual report
  • Nov 12, 2026 Bolt acquired Prana Therapies, making its pipeline the development focus Prana’s PRA-216 became the primary development focus, with Phase 2 studies in asthma, atopic dermatitis and COPD.

Growing. Revenue grew 6.1x in 4 years, from $1.3M in FY2021 to $7.7M in FY2025, about 57% a year.

A new clinical focus The former lead immune-stimulating antibody conjugate program has been discontinued. The latest report centers clinical development on a different tumor-targeting conjugate, with the other pipeline programs on hold.

Who Do They Compete With?

Competes with Pfizer, Day One Biopharmaceuticals, and Eikon Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support